Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN) Read more
FDA approves Novartis Cosentyx as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade Read more
GSK enters agreement to obtain exclusive license for JNJ-3989 to expand the development of bepirovirsen Read more
Vect-Horus Enters Exclusive License Agreement with Novo Nordisk to Develop Targeted Therapeutics Read more
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) Read more